← All supplements
Limited evidenceGut health

Xylooligosaccharides (XOS)

A prebiotic that raises bifidobacteria at unusually low doses, around 1–3 g per day. The microbiome effect is repeatable in small trials, but clinical outcomes have barely been studied.

Evidence last reviewed: August 2026

What the science says

  • Bifidogenic effect at low doses Moderate evidence

    A double-blind, placebo-controlled crossover trial in healthy adults found that 1.4–2.8 g/day of XOS increased bifidobacteria and slightly modulated immune markers. An earlier controlled study reached the same conclusion: XOS raises bifidobacteria but not lactobacilli.

  • Metabolic effects in prediabetes Limited evidence

    A small pilot study in healthy and prediabetic adults found XOS altered gut bacteria, but it was underpowered for glucose or clinical endpoints and had no proper control arm for those outcomes.

  • Digestive symptoms Limited evidence

    No adequately sized randomized trial has tested XOS for constipation, IBS or bloating as a primary outcome.

Dosage & safety

Studied doseTrials used 1.4–2.8 g per day; commercial products commonly supply 1–2 g. Its selling point is that it works at a much lower dose than FOS or inulin.
SafetyBetter tolerated than most prebiotics because of the low dose, but gas and bloating are still possible. Long-term data in humans are scarce.

Scientific references

Where to buy

Referral link — this site may earn a commission on purchases.

Related in Gut health